Sphingosine-kinase-1 expression is associated with improved overall survival in high-grade serous ovarian cancer
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1432-1335
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Sphingosine-kinase-1 expression is associated with improved overall survival in high-grade serous ovarian cancer ; volume:147 ; number:5 ; day:3 ; month:3 ; year:2021 ; pages:1421-1430 ; date:5.2021
Journal of cancer research and clinical oncology ; 147, Heft 5 (3.3.2021), 1421-1430, 5.2021
- Urheber
-
Hanker, L. C.
El-Balat, A.
Drosos, Z.
Kommoss, S.
Karn, T.
Holtrich, U.
Gitas, G.
Graeser-Mayer, M.
Anglesio, M.
Huntsman, D.
Rody, A.
Gevensleben, H.
Hoellen, F.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s00432-021-03558-x
- URN
-
urn:nbn:de:101:1-2021052722350119571633
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:57 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Hanker, L. C.
- El-Balat, A.
- Drosos, Z.
- Kommoss, S.
- Karn, T.
- Holtrich, U.
- Gitas, G.
- Graeser-Mayer, M.
- Anglesio, M.
- Huntsman, D.
- Rody, A.
- Gevensleben, H.
- Hoellen, F.
- SpringerLink (Online service)
Ähnliche Objekte (12)
High-grade serous ovarian cancer: the clone wars
First-Line Management of Advanced High-Grade Serous Ovarian Cancer
PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer
Principles of dormancy evident in high-grade serous ovarian cancer
Tumor Evolution and Heterogeneity in High-Grade Serous Ovarian Cancer
MRI for differentiating ovarian endometrioid adenocarcinoma from high-grade serous adenocarcinoma
No evidence for PALB2 methylation in high-grade serous ovarian cancer
Biological and prognostic value of ETV5 in high-grade serous ovarian cancer
Clinical relevance of TP53 hotspot mutations in high-grade serous ovarian cancers
Immunotherapy that improves response to chemotherapy in high-grade serous ovarian cancer
High-throughput approaches for precision medicine in high-grade serous ovarian cancer
Immune cell landscapes are associated with high-grade serous ovarian cancer survival
High-grade serous ovarian cancer: the clone wars
First-Line Management of Advanced High-Grade Serous Ovarian Cancer
PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer
Principles of dormancy evident in high-grade serous ovarian cancer
Tumor Evolution and Heterogeneity in High-Grade Serous Ovarian Cancer
MRI for differentiating ovarian endometrioid adenocarcinoma from high-grade serous adenocarcinoma
No evidence for PALB2 methylation in high-grade serous ovarian cancer
Biological and prognostic value of ETV5 in high-grade serous ovarian cancer
Clinical relevance of TP53 hotspot mutations in high-grade serous ovarian cancers
Immunotherapy that improves response to chemotherapy in high-grade serous ovarian cancer
High-throughput approaches for precision medicine in high-grade serous ovarian cancer
Immune cell landscapes are associated with high-grade serous ovarian cancer survival
High-grade serous ovarian cancer: the clone wars
First-Line Management of Advanced High-Grade Serous Ovarian Cancer
PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer
Principles of dormancy evident in high-grade serous ovarian cancer
Tumor Evolution and Heterogeneity in High-Grade Serous Ovarian Cancer
MRI for differentiating ovarian endometrioid adenocarcinoma from high-grade serous adenocarcinoma
No evidence for PALB2 methylation in high-grade serous ovarian cancer
Biological and prognostic value of ETV5 in high-grade serous ovarian cancer
Clinical relevance of TP53 hotspot mutations in high-grade serous ovarian cancers
Immunotherapy that improves response to chemotherapy in high-grade serous ovarian cancer
High-throughput approaches for precision medicine in high-grade serous ovarian cancer